Please assess the completion status of the following clinical trial:

Trial Title: Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bleeding peptic ulcer: Among patients suspected to have upper GI bleeding based on hematemesis or melena, those with peptic ulcers(Forrest I, IIa and IIb) in whom active bleeding, non-bleeding visible vessels and fresh blood clots are observed on upper GI endoscopy performed within 24 hours after the hospitalization~* patients who achieved primary hemostasis with endoscopic hemostasis procedure via upper GI endoscopy~Exclusion Criteria:~* Patients who refuse endoscopic procedure~* Patients with complications from gastric ulcer that require operative treatment prior to upper GI endoscopic treatment(e.g., gastric outlet obstruction, peptic ulcer perforation)~* Pregnancy~* Patients with serious concurrent diseases such as malignant tumors or end-stage diseases~* History of previous gastrectomy or vagotomy~* Known hypersensitivity to proton pump inhibitors~* Elderly patients~* Epilepsy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rabeprazole sodium (Type: EXPERIMENTAL): Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
- Omeprazole (Type: ACTIVE_COMPARATOR): Intravenous Omeprazole 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).